CSL (CSL) Stock Overview

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.

CSL Stock Information

Symbol

CSL

Address

655 Elizabeth StreetMelbourne, VIC 3000Australia

Founded

Trading hours

10:00 AM - 4:00 PM AEST

Website

https://www.csl.com.au

Country

🇦🇺 Australia

Phone Number

61 3 9389 1911

CSL (CSL) Price Chart

CSL Overview: Key Details and Summary

Stock data	2023	Change
Price	$171.90	N/A
Market Cap	$128.90B	N/A
Shares Outstanding	749.88M	4.48%
Employees	32.06K	N/A
Shareholder Equity	27.29B	22.28%

Valuation	2023	Change
P/S Ratio	6.39	N/A
P/B Ratio	4.72	N/A
P/FCF	92.62	N/A

Dividends	2023	Change
Dividend Yield	1.47%	N/A
Dividend per share	2.5298	N/A
Dividend Payout Ratio	0.5521	N/A

Growth	2023	Change
WACC	0.0203	N/A
CAPEX	-1.71B	N/A
Return on Equity	0.1259	N/A

Earnings	2023	Change
Revenue	$20.17B	N/A
Earnings	$3.44B	N/A
Free Cash Flow	$1.39B	N/A
Gross Margin	0.5092	N/A
Operating Margin	0.1596	N/A
Net income margin	0.1703	N/A
FCF Margin	0.069	N/A

Financial Strength	2023	Change
Total Assets	$55.48B	N/A
Total Debt	$18.72B	N/A
Cash on Hand	$2.37B	N/A
Debt to Equity	$1.03	9.33%
Cash to Debt	0.1266	-88.28%
Current Ratio	$2.01	-13.23%